Skip to main content

Advertisement

Table 3 Quality of treatment with ACT

From: Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial

Per-Protocol Site 1 Site 2
Treatment adherencea AL (N = 176) AQAS (N = 176) Difference in means 95% CI p-value AL (N = 173) AQAS (N = 181) Difference in means 95% CI p-value
Mean  % of treatment (SD)b 99.8% (2.5) 98.6% (7.9) 1.17 − 0.09, 2.42 0.068 97.0% (12.8) 99.2% (6.3) − 2.19 − 4.37, 0.00 0.050
  1. aProportion of all tablets received − information on the number of tablets taken is missing from one participant in the AL group at Site 1 (n = 174). Measure of Effect = Difference of means; AQAS is the reference group
  2. bPercent of treatment = total number of tablets taken by the patient/total number of tablets prescribed
  3. cOdds Ratios were calculated using logistic regression, with ORs calculated using AQAS as the reference group
  4. dDose is defined as the number of tablets prescribed by weight or age. For AQAS: 1 tablet per day for three days. For AL: 5 to < 15 kg = 1 tablet twice a day for 3 days, 15 to < 25 kg = 2 tablets twice a day for three days
  5. eTiming is defined as the number of times per day the treatment should be taken. For AQAS: once daily. For AL: two times per day
  6. fDuration is defined as the number of days the treatment should be taken. For both AQAS and AL: 3 days
  7. gCorrect treatment = correct dose + correct timing + correct duration, in which the criteria for all three factors (as above) are met
Correct treatmentc AL (N = 179) AQAS (N = 174) Odds Ratio 95% CI p-value AL (N = 178) AQAS (N = 176) Odds ratio 95% CI p-value
Correct dosed 163 (93.1%) 144 (83.7%) 2.64 1.30, 5.39 0.008 128 (77.6%) 149 (88.7%) 0.44 0.24, 0.81 0.008
Correct timinge 163 (93.1%) 166 (96.5%) 0.49 0.18, 1.34 0.165 136 (82.4%) 163 (97.0%) 0.14 0.05, 0.38 < 0.001
Correct durationf 172 (98.3%) 170 (98.8%) 0.67 0.11, 4.09 0.668 156 (95.6%) 164 (97.6%) 0.42 0.13, 1.40 0.159
Correct treatmentg 154 (88.0%) 140 (81.4%) 1.68 0.92, 3.04 0.089 125 (75.8%) 148 (88.1%) 0.42 0.23, 0.76 0.004
  1. aProportion of all tablets received − information on the number of tablets taken is missing from one participant in the AL group at Site 1 (n = 174). Measure of Effect = Difference of means; AQAS is the reference group
  2. bPercent of treatment = total number of tablets taken by the patient/total number of tablets prescribed
  3. cOdds Ratios were calculated using logistic regression, with ORs calculated using AQAS as the reference group
  4. dDose is defined as the number of tablets prescribed by weight or age. For AQAS: 1 tablet per day for three days. For AL: 5 to < 15 kg = 1 tablet twice a day for 3 days, 15 to < 25 kg = 2 tablets twice a day for three days
  5. eTiming is defined as the number of times per day the treatment should be taken. For AQAS: once daily. For AL: two times per day
  6. fDuration is defined as the number of days the treatment should be taken. For both AQAS and AL: 3 days
  7. gCorrect treatment = correct dose + correct timing + correct duration, in which the criteria for all three factors (as above) are met
Intention-to-treat Site 1 Site 2
Treatment adherencea AL (N = 175) AQAS (N = 172) Difference in means 95% CI p-value AL (N = 165) AQAS (N = 168) Difference in means 95% CI p-value
Mean  % of treatment (SD)b 99.8% (2.5) 98.7% (7.9) 1.14 − 0.09, 2.36 0.069 97.0% (12.7) 99.1% (6.0) − 2.30 − 4.40, − 0.19 0.032
  1. aProportion of all tablets received − information on the number of tablets taken is missing from one participant in the AL group at Site 1 (n = 174). Measure of Effect = Difference of means; AQAS is the reference group
  2. bPercent of treatment = total number of tablets taken by the patient/total number of tablets prescribed
  3. cOdds Ratios were calculated using logistic regression, with ORs calculated using AQAS as the reference group
  4. dDose is defined as the number of tablets prescribed by weight or age. For AQAS: 1 tablet per day for three days. For AL: 5 to < 15 kg = 1 tablet twice a day for 3 days, 15 to < 25 kg = 2 tablets twice a day for three days
  5. eTiming is defined as the number of times per day the treatment should be taken. For AQAS: once daily. For AL: two times per day
  6. fDuration is defined as the number of days the treatment should be taken. For both AQAS and AL: 3 days
  7. gCorrect treatment = correct dose + correct timing + correct duration, in which the criteria for all three factors (as above) are met
Correct treatmentc AL (N = 175) AQAS (N = 172) Odds Ratio 95% CI p-value AL (N = 165) AQAS (N = 168) Odds Ratio 95% CI p-value
Correct dosed 166 (92.7%) 146 (83.9%) 2.45 1.22, 4.90 0.011 138 (77.5%) 155 (88.1%) 0.47 0.26, 0.83 0.010
Correct timinge 166 (92.7%) 168 (96.6%) 0.45 0.17, 1.23 0.120 149 (83.7%) 170 (96.6%) 0.18 0.07, 0.45 < 0.001
Correct durationf 179 (97.8%) 174 (98.9%) 0.51 0.09, 2.81 0.439 169 (94.9%) 171 (97.2%) 0.55 0.18, 1.67 0.291
Correct treatmentg 156 (87.2%) 142 (81.6%) 1.53 0.85, 2.74 0.153 135 (75.8%) 154 (87.5%) 0.45 0.26, 0.79 0.005
  1. aProportion of all tablets received − information on the number of tablets taken is missing from one participant in the AL group at Site 1 (n = 174). Measure of Effect = Difference of means; AQAS is the reference group
  2. bPercent of treatment = total number of tablets taken by the patient/total number of tablets prescribed
  3. cOdds Ratios were calculated using logistic regression, with ORs calculated using AQAS as the reference group
  4. dDose is defined as the number of tablets prescribed by weight or age. For AQAS: 1 tablet per day for three days. For AL: 5 to < 15 kg = 1 tablet twice a day for 3 days, 15 to < 25 kg = 2 tablets twice a day for three days
  5. eTiming is defined as the number of times per day the treatment should be taken. For AQAS: once daily. For AL: two times per day
  6. fDuration is defined as the number of days the treatment should be taken. For both AQAS and AL: 3 days
  7. gCorrect treatment = correct dose + correct timing + correct duration, in which the criteria for all three factors (as above) are met